首页> 外文期刊>Expert opinion on biological therapy >Peptide aptamers: recent developments for cancer therapy.
【24h】

Peptide aptamers: recent developments for cancer therapy.

机译:肽适体:癌症治疗的最新进展。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

During the past two decades, our understanding of oncogenesis has advanced considerably and many new signalling pathways have been identified. Differences in signalling events that distinguish normal cells from tumour cells provide new targets for the development of anticancer agents. Peptide aptamers are small peptide sequences that have been selected to recognise a predetermined target protein domain and are potentially able to interfere with its function. They represent useful molecules for manipulating protein function in vivo. The isolation and use of specific peptide aptamers as inhibitors of individual signalling components, essential in cancer development and progression, provides a new challenge for drug development. Although peptides make up only a small fraction of current therapeutics, their potential is being enhanced by new developments affecting their modification, stability, delivery and their successful application in preclinical settings. This review summarises the methods that can beused for the isolation and delivery of peptide aptamers, as well as the important achievements that have been made using such peptide aptamers in different systems. The applicability of peptide aptamers as novel cancer therapeutics will be discussed.
机译:在过去的二十年中,我们对致癌作用的了解已大大提高,并且已发现许多新的信号传导途径。区分正常细胞和肿瘤细胞的信号传递事件的差异为抗癌药的发展提供了新的靶点。肽适体是小的肽序列,其已被选择以识别预定的靶蛋白结构域并且潜在地能够干扰其功能。它们代表在体内操纵蛋白质功能的有用分子。特定肽适体的分离和使用作为单个信号成分的抑制剂(对癌症的发展和进程至关重要),为药物开发提出了新的挑战。尽管肽仅占当前疗法的一小部分,但由于其修饰,稳定性,递送及其在临床前环境中成功应用的新进展,肽的潜力正在增强。这篇综述总结了可用于分离和递送肽适体的方法,以及在不同系统中使用此类肽适体所取得的重要成就。将讨论肽适体作为新型癌症治疗剂的适用性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号